ReviewCurrent treatment options in oncology2015
Microsatellite instability testing and its role in the management of colorectal cancer.
Review in Current treatment options in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 225 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
225 citing papers in PubMed, 6 syntheses or guidelines pooled it, 433 citations in OpenAlex.
- Microsatellite instability and mismatch repair deficiency prevalence among Hispanic/Latino individuals with colorectal cancer: a systematic review and meta-analysis.International journal of colorectal disease · 2026Pooled it
- Mismatch repair protein deficiency and its implications on distant metastasis in colorectal cancer: A comprehensive analysis.Cancer medicine · 2024Pooled it
- The mechanisms and drug therapies of colorectal cancer and epigenetics: bibliometrics and visualized analysis.Frontiers in pharmacology · 2024Pooled it
- Systematic review of machine learning-based radiomics approach for predicting microsatellite instability status in colorectal cancer.La Radiologia medica · 2023Pooled it
- Artificial Intelligence for Predicting Microsatellite Instability Based on Tumor Histomorphology: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review.International journal of molecular sciences · 2020Pooled it
- Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.Journal for immunotherapy of cancer · 2021Trial
- Immune Checkpoints in Circulating and Tumor-Infiltrating CD4Frontiers in immunology · 2019Trial
- Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.The lancet. Gastroenterology & hepatology · 2018Trial
- Immune evasion in locally advanced mismatch repair-deficient microsatellite instability-high colorectal cancer: Reduced T-cell infiltration and upregulation of epithelial IDO1 expression.Oncoimmunology · 2026Article
- Profound alterations of cancer transcriptomes by the RNase L inhibitor ABCE1 through the modulation of UU/UA-dinucleotide rich transcript abundance.RNA biology · 2026Article
- Immune-epithelial crosstalk governs immune checkpoint inhibitor efficacy in colorectal cancer.iScience · 2026Article
- Pre-treatment prediction of microsatellite instability in colon cancer: a nomogram model combining clinicopathological features and pre-treatment CT-based radiomics.BMC medical imaging · 2026Article
- Multitask radioclinical decision stratification in non-metastatic colon cancer: integrating MMR status, pT staging, and high-risk pathological factors.Abdominal radiology (New York) · 2026Article
- Predicting therapeutic responses in metastatic colorectal cancer through personalized functional profiling of patient-derived spheroids.NPJ precision oncology · 2026Article
- Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology.Oncology and therapy · 2026Article
- Association between serum uric acid levels and clinical outcomes of immunotherapy in advanced colorectal cancer patients.BMC cancer · 2026Article
- An evolving pathology: colorectal cancer with metastasis to the axilla; the treatment approach and response.Journal of surgical case reports · 2026Article
- Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers.Journal of medicinal chemistry · 2025Article
- Immunotherapy-induced microsatellite instability status shift in recurrent perihilar cholangiocarcinoma: A case report.Human vaccines & immunotherapeutics · 2025Article
165 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Opinion statement: TNM stage remains the key determinant of patient prognosis after surgical resection of colorectal cancer (CRC), and informs treatment decisions. However, there is considerable stage-independent variability in clinical outcome that is likely due to molecular heterogeneity. This variability underscores the need for robust prognostic and predictive biomarkers to guide therapeutic decision-making including the use of adjuvant chemotherapy. Although the majority of CRCs develop via a chromosomal instability pathway, approximately 12-15 % have deficient DNA mismatch repair (dMMR) which is characterized in the tumor by microsatellite instability (MSI). Tumors with the dMMR/MSI develop from a germline mutation in an MMR gene (MLH1, MSH2, MSH6, PMS2), i.e., Lynch syndrome, or more commonly from epigenetic inactivation of MLH1 MMR gene. CRCs with dMMR/MSI status have a distinct phenotype that includes predilection for the proximal colon, poor differentiation, and abundant tumor-infiltrating lymphocytes. Consistent data indicate that these tumors have a better stage-adjusted survival compared to proficient MMR or microsatellite stable (MSS) tumors and may respond differently to 5-fluorouracil-based adjuvant chemotherapy. To increase the identification of dMMR/MSI patients in clinical practice that includes those with Lynch syndrome, it is recommended that all resected CRCs to be analyzed for MMR status. Available data indicate that patients with stage II dMMR CRCs have an excellent prognosis and do not benefit from 5-fluorouracil (FU)-based adjuvant chemotherapy which supports their recommended management by surgery alone. In contrast, the benefit of standard adjuvant chemotherapy with the FOLFOX regiment in stage III dMMR CRC patients awaits further study and therefore, all patients should be treated with standard adjuvant FOLFOX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.